Hyperuricemia and gout are associated with cancer incidence and mortality: A meta‐analysis based on cohort studies

2019 ◽  
Vol 234 (8) ◽  
pp. 14364-14376 ◽  
Author(s):  
Yuxiu Xie ◽  
Peng Xu ◽  
Kang Liu ◽  
Shuai Lin ◽  
Meng Wang ◽  
...  
Keyword(s):  
Cohort Studies ◽  
Cancer Incidence ◽  
Meta Analysis ◽  
Incidence And Mortality

scholarly journals 25-Hydroxyvitamin D and Total Cancer Incidence and Mortality: A Meta-Analysis of Prospective Cohort Studies

Nutrients ◽  
2019 ◽  
Vol 11 (10) ◽  
pp. 2295 ◽  
Author(s):  
Jianmin Han ◽  
Xiaofei Guo ◽  
Xiao Yu ◽  
Shuang Liu ◽  
Xinyue Cui ◽  
...  
Keyword(s):  
Cohort Studies ◽  
Cancer Incidence ◽  
Cancer Mortality ◽  
Meta Analysis ◽  
Hydroxyvitamin D ◽  
Prospective Cohort Studies ◽  
Incidence And Mortality ◽  
Total Cancer ◽  
25 Hydroxyvitamin D ◽  
Risk Of Cancer

Epidemiological studies have suggested inconclusive associations between 25-hydroxyvitamin D and total cancer incidence and mortality. The aim of this study was to quantitatively assess these associations by combining results from prospective cohort studies. A systematic literature search was implemented in PubMed and Scopus databases in April 2019. Comparing the highest with the lowest categories, the multivariate-adjusted relative risks (RRs) and the corresponding 95% confidence intervals (CIs) were pooled using a random-effects model. A trend estimation was performed using a two-stage, dose-response, meta-analysis method. Twenty-three independent prospective studies were included for data synthesis. Eight studies investigated the association between 25-hydroxyvitamin D and the risk of cancer incidence (7511 events and 70,018 participants), and the summary estimate showed that 25-hydroxyvitamin D is marginally associated with cancer risk (Summary RR = 0.86; 95% CI: 0.73, 1.02; I2 = 70.8%; p = 0.001). Sixteen studies investigated the association between 25-hydroxyvitamin D and the risk of cancer mortality (8729 events and 101,794 participants), and a higher 25-hydroxyvitamin D concentration was inversely associated with the risk of cancer mortality (Summary RR = 0.81; 95% CI: 0.71, 0.93; I2 = 48.8%, p = 0.012). Dose-response analysis indicated that the risk of cancer incidence was reduced by 7% (RRs = 0.93; 95% CI: 0.91, 0.96), and the risk of cancer mortality was reduced by 2% (RRs = 0.98; 95% CI: 0.97, 0.99), with each 20 nmol/L increment of 25-hydroxyvitamin D concentration. This meta-analysis provides evidence that a higher 25-hydroxyvitamin D concentration is associated with a lower cancer incidence and cancer mortality.

Depression and anxiety in relation to cancer incidence and mortality: a systematic review and meta-analysis of cohort studies

2019 ◽  
Vol 25 (7) ◽  
pp. 1487-1499 ◽  
Author(s):  
Yun-He Wang ◽  
Jin-Qiao Li ◽  
Ju-Fang Shi ◽  
Jian-Yu Que ◽  
Jia-Jia Liu ◽  
...  
Keyword(s):  
Systematic Review ◽  
Cohort Studies ◽  
Cancer Incidence ◽  
Meta Analysis ◽  
Depression And Anxiety ◽  
Incidence And Mortality

scholarly journals Colonoscopic screening is associated with reduced Colorectal Cancer incidence and mortality: a systematic review and meta-analysis

2020 ◽  
Vol 11 (20) ◽  
pp. 5953-5970
Author(s):  
Jiaxin Zhang ◽  
Guang Chen ◽  
Zhiguo Li ◽  
Peng Zhang ◽  
Xiaoke Li ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Cancer Incidence ◽  
Meta Analysis ◽  
Incidence And Mortality ◽  
Colorectal Cancer Incidence

scholarly journals Efficacy and safety of chemopreventive agents on colorectal cancer incidence and mortality: systematic review and network meta-analysis

2018 ◽  
Vol Volume 10 ◽  
pp. 1433-1445 ◽  
Author(s):  
Sajesh K Veettil ◽  
Peerawat Jinatongthai ◽  
Surakit Nathisuwan ◽  
Nattawat Teerawattanapong ◽  
Siew Mooi Ching ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Systematic Review ◽  
Cancer Incidence ◽  
Meta Analysis ◽  
Efficacy And Safety ◽  
Chemopreventive Agents ◽  
Incidence And Mortality ◽  
Colorectal Cancer Incidence

scholarly journals Skin Cancer Incidence and Mortality in Spain: A Systematic Review and Meta-Analysis

2016 ◽  
Vol 107 (4) ◽  
pp. 318-328 ◽  
Author(s):  
A. Tejera-Vaquerizo ◽  
M.A. Descalzo-Gallego ◽  
M.M. Otero-Rivas ◽  
C. Posada-García ◽  
L. Rodríguez-Pazos ◽  
...  
Keyword(s):  
Systematic Review ◽  
Skin Cancer ◽  
Cancer Incidence ◽  
Meta Analysis ◽  
Incidence And Mortality

scholarly journals Cohort profile: the Women’s Health Accelerometry Collaboration

BMJ Open ◽  
2021 ◽  
Vol 11 (11) ◽  
pp. e052038
Author(s):  
Kelly R Evenson ◽  
John Bellettiere ◽  
Carmen C Cuthbertson ◽  
Chongzhi Di ◽  
Rimma Dushkes ◽  
...  
Keyword(s):  
Physical Activity ◽  
Cohort Studies ◽  
Women’S Health ◽  
Women's Health ◽  
Sedentary Behaviour ◽  
Cancer Diagnosis ◽  
Cancer Incidence ◽  
Cancer Surveillance ◽  
Cancer Outcomes ◽  
Incidence And Mortality

PurposeThis paper describes the Women’s Health Accelerometry Collaboration, a consortium of two prospective cohort studies of women age 62 years or older, harmonised to explore the association of accelerometer-assessed physical activity and sedentary behaviour with cancer incidence and mortality.ParticipantsA total of 23 443 women (age mean 73.4, SD 6.8) living in the USA and participating in an observational study were included; 17 061 from the Women’s Health Study (WHS) and 6382 from the Women’s Health Initiative Objective Physical Activity and Cardiovascular Health (WHI/OPACH) Study.Findings to dateAccelerometry, cancer outcomes and covariate harmonisation was conducted to align the two cohort studies. Physical activity and sedentary behaviour were measured using similar procedures with an ActiGraph GT3X+ accelerometer, worn at the hip for 1 week, during 2011–2014 for WHS and 2012–2014 for WHI/OPACH. Cancer outcomes were ascertained via ongoing surveillance using physician adjudicated cancer diagnosis. Relevant covariates were measured using questionnaire or physical assessments. Among 23 443 women who wore the accelerometer for at least 10 hours on a single day, 22 868 women wore the accelerometer at least 10 hours/day on ≥4 of 7 days. The analytical sample (n=22 852) averaged 4976 (SD 2669) steps/day and engaged in an average of 80.8 (SD 46.5) min/day of moderate-to-vigorous, 105.5 (SD 33.3) min/day of light high and 182.1 (SD 46.1) min/day of light low physical activity. A mean of 8.7 (SD 1.7) hours/day were spent in sedentary behaviour. Overall, 11.8% of the cohort had a cancer diagnosis (other than non-melanoma skin cancer) at the time of accelerometry measurement. During an average of 5.9 (SD 1.6) years of follow-up, 1378 cancer events among which 414 were fatal have occurred.Future plansUsing the harmonised cohort, we will access ongoing cancer surveillance to quantify the associations of physical activity and sedentary behaviour with cancer incidence and mortality.

Sign in / Sign up

Export Citation Format

Share Document